Tetrahydrocannabivarin

Research use only, not for human use.

Tetrahydrocannabivarin is a neutral cannabis receptor subtype (CB1) receptor antagonist, it can increases neural responding to rewarding and aversive stimuli, this effect profile suggests therapeutic activity in obesity, perhaps with a lowered risk of depressive side effects. Tetrahydrocannabivarin exhibits anticonvulsant effects in a piriform cortical brain slice model of epileptiform activity.

Tetrahydrocannabivarin is a neutral cannabis receptor subtype (CB1) receptor antagonist, it can increases neural responding to rewarding and aversive stimuli, this effect profile suggests therapeutic activity in obesity, perhaps with a lowered risk of depressive side effects. Tetrahydrocannabivarin exhibits anticonvulsant effects in a piriform cortical brain slice model of epileptiform activity.(In Vitro):At 3-1000 nanomol (nM), THCV did not prevent electrically induced contractions of mouse isolated vas deferens; though, the amount of THCV in this range formed dextral shifts in the log concentration-response curves of WIN and anandamide for electrically evoked contractions. These changes were not convoyed by a reduction in the maximal effect of any agonist. Nevertheless, at 3 millimolar (mM), THCV did lessen the contractile reaction of the vas deferens in a CB1 receptor antagonist (SR141716)-independent way. Moreover, THCV looks like SR141716 antagonist, which at high quantities also cooperates with non-CB1 targets.

delta9-Tetrahydrocannabivarin; THCV; CRM; Tetrahydrocannavarin

GPCR/G Protein

Cannabinoid Receptor

Cannabinoid Receptor

——

——

31262-37-0

286.4

C19H26O2

>98% (HPLC)

——

CCCc1cc(OC(C)(C)[C@H]2[C@H]3C=C(C)CC2)c3c(O)c1

——

(-20℃)

With Ice Pack

≥ 2 years